Pharmaceutical compositions for high-capacity targeted delivery

作者: William H. Gmeiner

DOI:

关键词:

摘要: Provided herein are aptamers and pharmaceutical compositions comprising the same. In some embodiments, aptamer selectively binds a protein of interest such as an extracellular receptor (e.g., cancer cell protein, which may be differentially expressed in embodiments). is directly linked by covalent bonding via geminal diamine linkage) to from 2 10 toxin compounds. Also provided method selecting that specifically interest, wherein embodiments comprises at least one binding site for or more active primer regions flanking variable region pool contains 1 mismatches with respect said forward reverse primer.

参考文章(40)
Jean-Marc Balloul, Jerome Lacoste, Suzy Scholl, Combination products for use in antitumoral treatment ,(2003)
William H. Gmeiner, Patrick L. Iversen, Oligonucleotide prodrugs containing 5-fluorouracil ,(1995)
Bruce Sullenger, Eli Gilboa, Smita K. Nair, Sandra Santulli-Marotto, Chris Rusconi, Multivalent RNA Aptamers That Inhibit CTLA-4 and Enhance Tumor Immunity Cancer Research. ,vol. 63, pp. 7483- 7489 ,(2003)
Carl-Henrik Heldin, Kristofer Rubin, Arne Ostman, Kristian Pietras, Method for treatment of tumors using nucleic acid ligands to PDGF ,(2001)
Mark E. Davis, Inhibitor nucleic acids ,(2006)
Eli Gilboa, Fernando Pastor, Aptamer-targeted costimulatory ligand aptamer ,(2010)
Martin Stanton, Markus Kurz, Aptamer-toxin molecules and methods for using same ,(2003)
Matthew Wecker, Kirk Jensen, Bruce Eaton, Larry Gold, Drew Smith, Systematic evolution of ligands by exponential enrichment: tissue SELEX ,(1996)